Prostate-specific Membrane Antigen Positron Emission Tomography–detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation
- 1 March 2021
- journal article
- research article
- Published by Elsevier in European Urology Focus
- Vol. 7 (2) , 309-316
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialThe Lancet Oncology, 2016
- Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialThe Lancet Oncology, 2016
- Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional AnalysisEuropean Urology, 2016
- Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term SurvivalEuropean Urology, 2015
- Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate CancerEuropean Urology, 2015
- Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 TrialEuropean Urology, 2014
- Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceRadiation Oncology, 2014
- Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO GuidelineJournal of Urology, 2013
- Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancerCancer, 2009
- The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007